Microbial Ecosystem Therapeutics-4 clinical trials
How each study uses Microbial Ecosystem Therapeutics-4 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- MET-4
- 3
Studies by the year they started
3 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 3
University Health Network, Toronto (2) · Canadian Cancer Trials Group (1)
Studies
Open first, then newest update. How each study uses Microbial Ecosystem Therapeutics-4 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy PatientsActive, not recruitingPhase 2/3University Health Network, TorontoNCT03686202Written as MET-4
- Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2CompletedNot applicableUniversity Health Network, TorontoNCT03838601Written as MET-4
- PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell CarcinomaWithdrawnPhase 2Canadian Cancer Trials GroupNCT05743777Written as MET-4